Log In
Print
BCIQ
Print
Print this Print this
 

Riona, Zerenex, ferric citrate (JTT-751)

Also known as: Nephoxil

  Manage Alerts
Collapse Summary General Information
Company Panion & BF Biotech Inc.
DescriptionOral ferric iron-based phosphate binder
Molecular Target
Mechanism of ActionPhosphate binder
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentApproved
Standard IndicationHyperphosphatemia
Indication DetailsManage serum phosphorus and iron deficiency in anemic patients with non-dialysis dependent chronic kidney disease (CKD); Treat hyperphosphatemia in non-dialysis dependent patients with chronic kidney disease (CKD); Treat hyperphosphatemia in patients with chronic kidney disease (CKD); Treat hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis; Treat hyperphosphatemia in patients with end-stage renal disease (ESRD)
Regulatory Designation

U.S. - Special Protocol Assessment (Treat hyperphosphatemia in patients with end-stage renal disease (ESRD));
U.S. - Standard Review (Treat hyperphosphatemia in patients with chronic kidney disease (CKD));
EU - Standard Review (Treat hyperphosphatemia in patients with chronic kidney disease (CKD));
Japan - Standard Review (Treat hyperphosphatemia in patients with chronic kidney disease (CKD))

Partner

Japan Tobacco Inc.; Keryx Biopharmaceuticals Inc.; Torii Pharmaceutical Co. Ltd.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today